Ventoux Biosciences Press Releases

Published on March 12, 2024 - 20:50 GMT

Ventoux Biosciences Announces Positive Pre-Clinical Results, Initiates Fundraising Round to Advance Development

Ventoux Biosciences, Founded by Dupuytren's Patient, Announces Positive Anti-Fibrotic Effects with VEN-201 and Initiates Initial Fundraising Round ENCINITAS, CALIFORNIA, UNITED STATES, March 12, 2024 /⁨EINPresswire.com⁩/ -- Ventoux Biosciences Announces Positive Pre-Clinical Results for Fibrosis Treatment, Initiates Fundraising Round to Advance Development VEN-201 Demonstrated Positive Anti-Fibrotic Effects in a Bleomycin-Induced Dermal Fibrosis Model Ventoux Biosciences, Inc., a privately held …

Distribution channels: Agriculture, Farming & Forestry Industry, Aviation & Aerospace Industry ...
Published on December 26, 2023 - 23:18 GMT

Ventoux Biosciences Appoints Dr. Ken Lipson, PhD as Chief Scientific Officer

Ventoux Biosciences Elevates Leadership for Dupuytren’s Disease Therapies SAN DIEGO, CALIFORNIA, UNITED STATES, December 26, 2023 /⁨EINPresswire.com⁩/ -- Ventoux Biosciences, a trailblazing specialty pharmaceutical company dedicated to developing groundbreaking, first-line therapies for Dupuytren’s disease, proudly welcomes Dr. Ken Lipson, PhD, as its new Chief Scientific Officer and Vice President of Corporate Strategy. "Ken is a highly esteemed scientist whose invaluable contributions to our …

Distribution channels: Agriculture, Farming & Forestry Industry, Banking, Finance & Investment Industry ...
Published on April 25, 2023 - 09:00 GMT

Ventoux Biosciences Launches to Transform Disease Management for Fibrotic Disease

Dupuytren’s Disease Impacts Millions of Patients including Company Founder, Pharmaceutical Industry Veteran SAN DIEGO, CALIFORNIA, UNITED STATES, April 25, 2023 /⁨EINPresswire.com⁩/ -- Ventoux Biosciences, a privately held specialty pharmaceutical company, has launched with a mission to deliver life-changing therapies for patients with Dupuytren’s and related fibrotic diseases. The company initiated pre-clinical evaluation of its early-stage pipeline, VEN-201 and VEN-202, in Q2 2023. Dupuytren’s disease …

Distribution channels: Banking, Finance & Investment Industry, Business & Economy ...

Contact

Michelle Stansbury
Little Penguin PR

Share This Newsroom

Company/Organization

Ventoux Biosciences
315 South Coast Highway 101, Suite U245
Encinitas, California, 92024
United States
+1 760-621-8562
Visit Website

Facebook LinkedIn

About

Ventoux Biosciences is a biopharmaceutical company focused on acquiring, in-licensing, developing, and commercializing proprietary products for Dupuytren's Disease and related fibroproliferative, inflammatory conditions with significant unmet medical need.

https://www.ventouxbio.com/

The Newsroom of Ventoux Biosciences

Ventoux Biosciences Announces Positive Pre-Clinical Results, Initiates Fundraising Round to Advance Development

Ventoux Biosciences Appoints Dr. Ken Lipson, PhD as Chief Scientific Officer

Ventoux Biosciences Launches to Transform Disease Management for Fibrotic Disease